Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
B- Exenatide twice daily · 1 trial · 1 indication
Change in HbA1c from Baseline Visit 3 (Day 1) to study termination (Day 28)
| Arm | Type | Description |
|---|---|---|
| A1 - Placebo 0.04 mL twice daily | PLACEBO_COMPARATOR | - |
| A2 - Placebo 0.04 mL once daily | PLACEBO_COMPARATOR | - |
| A3 - Placebo 0.08 mL once daily | PLACEBO_COMPARATOR | - |
| B - Exenatide 10 mcg twice daily | EXPERIMENTAL | - |
| C - Exenatide 10 mcg once daily | EXPERIMENTAL | - |
| D - Exenatide 20 mcg once daily | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo 0.04 mL twice daily | DRUG | Subcutaneously injected, 0.04 mL, twice daily |
| Placebo 0.04 mL once daily | DRUG | Subcutaneously injected, 0.04 mL, once daily |
| Placebo 0.08 mL once daily | DRUG | Subcutaneously injected, 0.08 mL, once daily |
| B - Exenatide 10 mcg twice daily | DRUG | Subcutaneously injected, 10 mcg (0.04 mL), twice daily |
| C - Exenatide 10 mcg once daily | DRUG | Subcutaneously injected, 10 mcg (0.04 mL), once daily |
| Exenatide 20 mcg once daily | DRUG | Subcutaneously injected, 20 mcg (0.08 mL), once daily |
Inclusion Criteria: * Subject has type 2 diabetes mellitus treated with diet and exercise modification alone or in combination with one oral antidiabetic agent for no longer than 4 years. Exclusion Criteria: * Subject has a clinically significant history or presence of any of the following condit...
B- Exenatide twice daily is used for the treatment of Type 2 Diabetes Mellitus. It is a small molecule being developed by AstraZeneca PLC for metabolic conditions. The drug is currently in Phase 2 clinical development, with one completed trial evaluating its effect on glucose control in subjects with Type 2 Diabetes Mellitus.
B- Exenatide twice daily is being developed by AstraZeneca PLC, a pharmaceutical company listed on the stock exchange under the ticker AZN. The drug is in Phase 2 clinical development for the treatment of Type 2 Diabetes Mellitus, a metabolic condition.
B- Exenatide twice daily is in Phase 2 clinical development. It is an investigational drug for the treatment of Type 2 Diabetes Mellitus, and it has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug is not currently in active clinical trials.
B- Exenatide twice daily has one completed clinical trial, NCT00085969, titled "Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus." This Phase 2, randomized, double-blind, placebo-controlled trial enrolled 99 participants in the United States and is now completed.
B- Exenatide twice daily is a formulation of exenatide, a drug used for Type 2 Diabetes Mellitus. The name indicates the dosing frequency of twice daily. It is being developed by AstraZeneca PLC and is currently in Phase 2 clinical development, with one completed trial.